PDMP TTAC hosted and facilitated the Harold Rogers Prescription Drug Monitoring Program (PDMP) 2024 National Meeting took place on August 13-15, 2024 in Washington, D.C. Themed “PDMPs: Collaborating to Address the Prescription Drug Crisis,” the meeting was a resounding success. The conference offered valuable insights and fostered collaboration among the attendees, which included experts, policymakers, and stakeholders and with representation from 30 of the 54 PDMPs. The sessions included:
• Mariel Lifshitz, Senior Advisor, Office of the Assistant Attorney General, Department of Justice, and David P. Lewis, Senior Policy Advisor at the Bureau of Justice Assistance (BJA). They emphasized the importance of PDMPs in combating the opioid epidemic and highlighted the need for continued innovation and cooperation.
• Dr. Andrew Kolodny, Medical Director of the Opioid Policy Research Collaborative, delivered an exceptional keynote address on the current state of the opioid crisis and the path forward. His presentation set the tone for the conference, underscoring the urgency of the issue and the critical role of PDMPs in mitigating the crisis.
• e[PDMP]iology: Three Cases of Operationalizing PDMP Data for Epidemiologic Research: Dr. Chris Delcher shared innovative approaches to using PDMP data for public health research.
• The Effect of PDMPs’ Collaboration to Address the Prescription Drug Crisis: John L. Eadie discussed the impact of collaborative efforts on reducing prescription drug misuse. He also covered the rapid increase in stimulant prescribing and data provided by state PDMPs.
• Pragmatic Evaluations of PDMP Legislation: Jason Hoppe, DO, presented real-world evidence on the effectiveness of PDMP legislation.
• Controlled substance prescribing to mothers of infants born with neonatal abstinence syndrome.
• Implementing 42 CFR Part 2 regulations.
Networking opportunities allowed attendees to connect and share information about their systems, fostering a sense of community and collaboration. The event concluded with a call to action, urging all participants to continue their efforts in addressing the prescription drug crisis
Please check the box next to the following questions if the answer is 'yes'.
Please enter the applicable Event Date if there is an Event associated with this TTA.
When entering an Event Date, the Time is also required.
If the TTA is targeted to a particular audience or location, please complete the questions below.
Milestones are an element, activity, work product, or key task associated with completing the TTA (e.g. kick-off meeting, collect data from stake holders, deliver initial data analysis).
Please complete the fields below, if applicable, to create a milestone for this TTA.
Please respond to the Performance Metrics below. The Performance Metrics questions are based on the TTA Type indicated in the General Information section of the TTA.
Please submit a signed letter of support from your agency’s executive or other senior staff member. The letter can be emailed to or uploaded with this request. The letter should be submitted on official letterhead and include the following information:
- General information regarding the request for TTA services, i.e., the who, what, where, when, and why.
- The organizational and/or community needs specific to the request for TTA services.
- The benefits or anticipated outcomes from the receipt of TTA services.
By submitting this application to BJA NTTAC, I understand that upon approval of this application for TTA, the requestor agrees to keep BJA NTTAC informed of any circumstances that may impact the delivery of the TTA, including changes in the date of the event, event cancellation, or difficulties communicating with the assigned TTA provider.
Please call [site:phone] if you need further assistance completing this application.